SCHEMBL5138089

SCHEMBL5138089

CCCCN(Cc1cccc(Oc2ccccc2)c1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.46
HSD17B10 Q99714 2/20 0.46
C5AR1 P21730 1/20 0.44
BCHE P06276 4/20 0.40
TNK2 Q07912 1/20 0.40
ATP4A P20648 3/20 0.39
ATP4B P51164 3/20 0.39
CRHR1 P34998 2/20 0.39
PPARG P37231 2/20 0.39
PPARA Q07869 2/20 0.39
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135269 0.96 TSHR (0.51) TSHRHSD17B10C5AR1BCHETNK2
SCHEMBL5135794 0.95 TSHR (0.42) TSHRHSD17B10C5AR1BCHETNK2
SCHEMBL5072424 0.93 C5AR1 (0.45) TSHRHSD17B10C5AR1BCHETNK2
SCHEMBL5135705 0.93 CALM1 (0.45) TSHRC5AR1BCHEATP4AATP4B
SCHEMBL648091 0.92 C5AR1 (0.44) TSHRHSD17B10C5AR1BCHEATP4A
SCHEMBL5134991 0.91 C5AR1 (0.44) TSHRHSD17B10C5AR1TNK2ATP4A
SCHEMBL5170566 0.90 CALM1 (0.43) TSHRHSD17B10C5AR1BCHEATP4A
SCHEMBL5134931 0.90 CALM1 (0.44) TSHRHSD17B10C5AR1BCHEATP4A
SCHEMBL651691 0.89 C5AR1 (0.42) TSHRHSD17B10C5AR1BCHEATP4A
SCHEMBL5135861 0.89 CRHR1 (0.44) TSHRHSD17B10C5AR1BCHEATP4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed